Off-Label Use: US FDA Backs Away From ‘Totality Of Evidence’ Standard In Proposed Reg

 
• By Brenda Sandburg
  
FDA_Concept
FDA proposed rule clarifies how agency determines a company's intended use of a medical product • Source: Shutterstock

More from US FDA

More from Agency Leadership